Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
901-920 of 3,900 trials

Advanced Breast Cancer: Patritumab Deruxtecan Study

We are testing a new drug for patients with advanced breast cancer to see how well it works. The study will also analyze biomarkers to understand treatment responses better.

Advanced Breast CancerEfficacy phase (II)Oncology

Non-Small Cell Lung Cancer: DS-1062a Treatment Study

We are testing a new antibody-drug conjugate for patients with advanced non-small cell lung cancer. The study aims to see how effective it is and how individual responses may vary.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)Oncology

Advanced Breast Cancer: HER3-DXd Treatment Study

We are investigating a new drug for patients with inoperable advanced breast cancer who have progressed after previous treatment. The study aims to understand its safety and effectiveness, both alone and in combination with other therapies.

HER2-positive and HER2-low Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology

IgM Monoclonal Gammopathy: Zanubrutinib and Rituximab Study

We are investigating whether a new treatment combining Zanubrutinib with Rituximab can improve nerve function in patients with IgM monoclonal gammopathy and related nerve damage. The study will also look at safety and how well patients tolerate the treatment.

Anti-MAG Neuropathy>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyNeurology

Obesity Surgery: Opioid Sparing Care Pathway

We are studying a new pain management approach for patients undergoing obesity surgery to see if it helps reduce opioid use and improve recovery. This may lead to better health outcomes and less reliance on pain medications.

Postoperative PainObesity>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOtolaryngology

Ovarian Cancer: 68Ga-FAPI PET/CT Imaging Study

We are comparing a new imaging technique to standard methods for diagnosing and monitoring ovarian cancer. This study aims to see if the new method improves patient management and safety.

Ovarian Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyOtolaryngology

Osteoporosis Treatment: The OPTIMIST Study on Romosozumab

We are exploring the best ways to use romosozumab for osteoporosis treatment. Additionally, we’re investigating if it has any impact on insulin sensitivity.

Osteoporosis>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyInternal Medicine

Postoperative Recovery: Spinal Morphine vs. Intravenous Lidocaine

We are studying if adding spinal morphine to pain management helps patients recover better after robotic-assisted upper urinary tract surgery. The goal is to see if it reduces pain and speeds up recovery compared to standard treatment.

Kidney and Ureter Disorders6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineNephrologyOncologyOtolaryngologyUrology

Melanoma: Ipilimumab and Nivolumab Combination

We are testing a new treatment using two immunotherapy drugs for patients with high-risk stage II melanoma. The goal is to see if this combination can improve outcomes before surgery.

Stage II Melanoma6-12 monthsEfficacy phase (II)DermatologyOncology

TAK-881 for Primary Immunodeficiency Diseases

We are studying the long-term safety and tolerability of TAK-881 in individuals with Primary Immunodeficiency Diseases. This trial will also assess how well the treatment works and its effects on patients' quality of life.

Primary Immunodeficiency Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyInfectious Diseases

Type 2 Diabetes: Semaglutide for Bone Health

We are investigating whether oral Semaglutide can improve bone formation and strength in men and women with type 2 diabetes. This study focuses on those with normal or low bone mass.

Type 2 Diabetes1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementDiabetologyEndocrinologyRheumatology

Diabetes Foot Ulcers: Mesenchymal Stem Cells Study

We are exploring whether mesenchymal stem cells can help heal foot ulcers in people with diabetes. This early study aims to assess the safety and potential benefits of this treatment.

Diabetic Foot Ulcer>2 yearsSafety phase (I)Efficacy phase (II)DermatologyDiabetology

Persistent Atrial Fibrillation: Cryoballoon vs. Medication

We are studying whether early treatment with a cryoballoon is more effective than antiarrhythmic drugs for people with persistent atrial fibrillation. The trial also looks at how these treatments affect quality of life and healthcare needs.

Persistent Symptomatic Atrial Fibrillation>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiology

Cervical Cancer: ITHACA Immunotherapy Study

We are investigating the safety and immune effects of a new immunotherapy for early-stage cervical cancer. This study aims to understand how well this treatment works when delivered near the tumor.

Cervical Cancer6-12 monthsSafety phase (I)Gynecology and ObstetricsOncology

Basal Cell Carcinoma: Tirbanibulin (Klisyri®) Treatment Study

We are studying the effectiveness and safety of Tirbanibulin (Klisyri®) for treating superficial basal cell carcinoma. The trial will also look at how well patients tolerate the treatment and their overall satisfaction.

Superficial Basal Cell Carcinoma≤3 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesDermatology

Anal Cancer Treatment: Induction Chemotherapy Study

We are studying a new treatment approach for locally advanced anal squamous cell carcinoma to see if adding induction chemotherapy improves outcomes compared to standard treatment. This trial will help us understand its effects on survival and quality of life.

Locally Advanced Anal Squamous Cell CarcinomaConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Systemic Sclerosis: Anifrolumab Treatment Study

We are investigating whether Anifrolumab can improve symptoms and lung function in adults with systemic sclerosis. This study compares the new treatment to a placebo to see how well it works.

Systemic SclerosisImmune System DiseasesInterstitial Lung Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Severe Systemic Sclerosis: Stem Cell Treatment Study

We are investigating the safety of a new stem cell therapy for people with severe systemic sclerosis. The study aims to see if this treatment can improve skin and lung function.

Systemic Sclerosis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesInternal MedicineRheumatology

Severe Community-Acquired Pneumonia: AON-D21 Treatment Study

We are testing a new drug, AON-D21, as an additional treatment for patients with severe community-acquired pneumonia in intensive care. The study aims to assess its safety and effectiveness compared to a placebo.

Severe Community-Acquired Pneumonia≤3 monthsEfficacy phase (II)>20 visitsInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

High-Risk Aggressive B-Cell Lymphomas: R-Hyper-CVAD/R-MA Treatment

We are studying a new treatment approach for patients with high-risk aggressive B-cell lymphomas to see if it is effective and safe. This trial aims to improve outcomes for those facing this serious condition.

Lymphoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology